The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline’s investigational therapy GSK2857916 for the treatment of relapsed and refractory…
News
Health Canada has approved Imbruvica (ibrutinib) for the treatment of patients with steroid dependent or refractory chronic graft-versus-host disease (cGVHD), a life-threatening…
The California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to Poseida Therapeutics to support the clinical development of their P-BCMA-101…
A combination of Pomalyst (pomalidomide) and low-dose dexamethasone is cheaper than either Darzalex (daratumumab) or Kyprolis (carfilzomib) alone as a treatment for relapsed or…
Cellectar Biosciences is expanding its Phase 1 dose-escalating trial to evaluate the effectiveness and safety of multiple administrations of CLR 131 for the treatment of relapsed…
Patients with relapsed and refractory multiple myeloma lived roughly 3.6 months longer without their disease worsening when they received a once-weekly dose of…
Multiple myeloma patients with high levels of the EZH2 enzyme have shorter survival times, regardless of the treatment they receive, a British study reports. The…
A new study reports that the specific type of multiple myeloma (MM) may affect how long the drug Darzalex (daratumumab) remains in circulation, affecting its…
The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by National Health Service (NHS) in Scotland, has amended its initial decision…
Myeloma UK has launched a new clinical trial to identify the best treatment options for myeloma patients classified as high-risk. The study is the…
